Evidence,
Value and
Access
we are eva.
Driven by patient values.
People living with illnesses and their carers need to be central to decision making about access to new innovative technologies that have the potential to improve their quality and quantity of life. Payers have a part to play in ensuring that the health technologies are good investments for taxpayer’s dollars, however payers should not be the sole decision makers in this respect. Societal values, views and aspirations of people living with debilitating illnesses and their carers should have their say in the process for selection of health technology and policies that enable access to these technologies.
what we do.
Strategic Market Access Advisory
Access has become front and centre of any commercialisation effort. Majority of companies now have explicit goals and commitment to patient access at an executive level and in corporate mission statements, the role of access function has evolved from technical to a strategic one. It has become part of the agenda of multiple functions and the role of the Market Access function is rapidly evolving to become that of an orchestrator of Access across the organization. The traditional focus on core Access topics such as value, pricing and evidence at a product and portfolio level, as well as policy shaping in areas like value frameworks, health system strengthening, and affordability will continue. However, to achieve “Access as corporate objective” organisations need to embed access thinking as part of regular business of all other functions.
Integrated Evidence Generation Planning and Support
As market access become business critical, evidence generation can no longer focus on regulatory success or product differentiation from a medical perspective. Evidence generation needs to evolve to address the strategic needs of an organisation to influence developments broader than health care.
Policy and Advocacy
Balancing quality, innovation and sustainability remains a challenge for most healthcare systems. Equitable access to latest innovation under a universal health coverage is on the agenda of every jurisdiction. This is exerting enormous pressure on the industry to find new ways to make innovation available to patients everywhere. Policy shaping in areas like value frameworks, health system strengthening, and affordability are becoming critical to get the balance right.
Australian Sponsorship and Regulatory Support
EVA Healthcare is an experienced provider of sponsorship services and regulatory support for therapeutic goods in Australia.
New Product Planning - Commercialization
New Product Planning cannot just be guided purely by where the science is going but evolve to become more strategic about how it addresses access related policy positions and be informed by access ambitions to incorporate access perspectives including voice of customers (payers and consumers) early enough to make the right strategic trade-offs.
our partners
